Phase 4 N=40 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
Breast Cancer
Primary: Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC). — 1.78; 0.045 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Sentinel Node Detection in Clinical Early Stage Ovarian Cancer
Ovarian Cancer · Sentinel Node
Primary: Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments. — 21 participants
N/A N=89 Infrared Lymphangiography as a Method of Sentinel Node Identification
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Phase 2 N=62 Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)
Breast Cancer
Primary: The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel…
Phase 2 N=30 Lymphatic Mapping for Sentinel Node Identification and Analysis
Colorectal Cancer
Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 3 N=186 Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes
Early Phase 1 N=9 Gynecological Sentinel Lymph Nodes CEUS
Cervical Carcinoma · Malignant Female Reproductive System Neoplasm · Vaginal Carcinoma
Primary: Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) — 17 sentinel…
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
Phase 3 N=5,611 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
Breast Cancer
Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants
N/A N=160 SentiMag® Intraoperative Comparison in Breast Cancer
Breast Cancer
Primary: Number of Participants With Detected Lymph Nodes — 145 Participants
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Early Phase 1 N=10 ICG and SLN Mapping
Breast Cancer
Primary: Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Lymph Node Level — 100 percent concordance
N/A N=50 Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy
Multiple Myeloma · Breast Cancer
Primary: Relative Node Detection Sensitivity — 88.5; 94.2 Percentage (%) of SLNs detected
N/A N=200 Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG
Endometrial Cancer
Primary: Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes. — 1.25; 2.03 nodes
N/A N=28,291 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ
Ductal Carcinoma In Situ
Primary: Side Effects (Claim-based Measure), Including Lymphedema, Seroma, Wound Infection, or Pain — 534; 404; 23; 60 Participants — p=<.001
Phase 3 N=152 A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
Breast Cancer · Lymph Node Mapping · Sentinel Lymph Node Biopsy
Primary: Proportion of Lymph Nodes Identified by IC2000/SPY-PHI Compared to the Proportion of Lymph Nodes Identified by Tc99m/Gamma Probe — 360; 266 Lymph Nodes — p=<0.0001
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Phase 3 N=6 A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Pediatric Patients With Solid Tumors
Primary: % of Patients in Whom a Sentinel Lymph Node is Identified
Phase 3 N=35 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
Sentinel Lymph Node · Melanoma (Skin) · Breast Cancer
Primary: Number of Participants Where the First, Second and Third Sentinel Nodes Localized With the Use of Fluorescence Imaging Alone — 29; 9; 0 Participants
Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
N/A N=21 Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Breast Cancer
Primary: Number of Breast Cancer Participants With Sentinel Lymph Nodes (SLN) Identification Using the CEUS Technique — 20 Participants
N/A N=228 Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
Intraductal Carcinoma and Lobular Carcinoma in Situ
Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants
N/A N=430 Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
Endometrial Cancer · Cervical Cancer
Primary: Estimate the Sensitivity of the Sentinel Lymph Node — 418 Participants
Phase 2 N=90 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
N/A N=9 Intraoperative Evaluation of Axillary Lymphatics
Lymphedema · Surgery · Breast Cancer
Primary: Number of Cases Where Lymphatics Were Visualized by Blue Dye Versus by ICG Using the OnLume Imaging System — 5; 9 Participants
Phase 2 N=3 Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
Phase 3 N=100 Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer
Breast Neoplasms
Primary: Number of Patients With Less Than Two Lymph Nodes Detected — 22; 20 Participants